|
1
|
Mendez M, Custodio A and Provencio M: New
molecular targeted therapies for advanced non-small-cell lung
cancer. J Thorac Dis. 3:30–56. 2011.PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
3
|
Roy M, Luo YH, Ye M and Liu J: Nonsmall
cell lung cancer therapy: insight into multitargeted small-molecule
growth factor receptor inhibitors. Biomed Res Int.
2013:9647432013.PubMed/NCBI
|
|
4
|
Majeti BK, Lee JH, Simmons BH and Shojaei
F: VEGF is an important mediator of tumor angiogenesis in malignant
lesions in a genetically engineered mouse model of lung
adenocarcinoma. BMC Cancer. 13:2132013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen CT and Hung MC: Beyond anti-VEGF:
dual-targeting antiangiogenic and antiproliferative therapy. Am J
Transl Res. 5:393–403. 2013.PubMed/NCBI
|
|
6
|
Dempke WC, Suto T and Reck M: Targeted
therapies for non-small cell lung cancer. Lung Cancer. 67:257–274.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li J, Pan YY and Zhang Y: Sorafenib
combined with gemcitabine in EGFR-TKI-resistant human lung cancer
cells. Oncol Lett. 5:68–72. 2013.PubMed/NCBI
|
|
8
|
Khan Z, Khan N, Tiwari RP, Sah NK, Prasad
GB and Bisen PS: Biology of Cox-2: an application in cancer
therapeutics. Curr Drug Targets. 12:1082–1093. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kao J, Sikora AT and Fu S: Dual EGFR and
COX-2 inhibition as a novel approach to targeting head and neck
squamous cell carcinoma. Curr Cancer Drug Targets. 9:931–937. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wei D, Wang L, He Y, Xiong HQ, Abbruzzese
JL and Xie K: Celecoxib inhibits vascular endothelial growth factor
expression in and reduces angiogenesis and metastasis of human
pancreatic cancer via suppression of Sp1 transcription factor
activity. Cancer Res. 64:2030–2038. 2004. View Article : Google Scholar
|
|
11
|
Jeon YW and Suh YJ: Synergistic apoptotic
effect of celecoxib and luteolin on breast cancer cells. Oncol Rep.
29:819–825. 2013.PubMed/NCBI
|
|
12
|
Cervello M, Bachvarov D, Lampiasi N, et
al: Novel combination of sorafenib and celecoxib provides
synergistic anti-proliferative and pro-apoptotic effects in human
liver cancer cells. PLoS One. 8:e655692013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Morisaki T, Umebayashi M, Kiyota A, et al:
Combining celecoxib with sorafenib synergistically inhibits
hepatocellular carcinoma cells in vitro. Anticancer Res.
33:1387–1395. 2013.PubMed/NCBI
|
|
14
|
Tai MH, Weng CH, Mon DP, Hu CY and Wu MH:
Ultraviolet C irradiation induces different expression of
cyclooxygenase 2 in NIH 3T3 cells and A431 cells: the roles of
COX-2 are different in various cell lines. Int J Mol Sci.
13:4351–4366. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fulzele SV, Chatterjee A, Shaik MS,
Jackson T and Singh M: Inhalation delivery and anti-tumor activity
of celecoxib in human orthotopic non-small cell lung cancer
xenograft model. Pharm Res. 23:2094–2106. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Murakami M, Zhao S, Zhao Y, et al:
Increased intratumoral fluorothymidine uptake levels following
multikinase inhibitor sorafenib treatment in a human renal cell
carcinoma xenograft model. Oncol Lett. 6:667–672. 2013.
|
|
17
|
Boutros T, Chevet E and Metrakos P:
Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase
regulation: roles in cell growth, death, and cancer. Pharmacol Rev.
60:261–310. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Das M and Wakelee H: Targeting VEGF in
lung cancer. Expert Opin Ther Targets. 16:395–406. 2012. View Article : Google Scholar
|
|
19
|
Pasqualetti G, Ricciardi S, Mey V, Del
Tacca M and Danesi R: Synergistic cytotoxicity, inhibition of
signal transduction pathways and pharmacogenetics of sorafenib and
gemcitabine in human NSCLC cell lines. Lung Cancer. 74:197–205.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Giovannetti E, Labots M, Dekker H, et al:
Molecular mechanisms and modulation of key pathways underlying the
synergistic interaction of sorafenib with erlotinib in
non-small-cell-lung cancer (NSCLC) cells. Curr Pharm Des.
19:927–939. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ferrario A, Fisher AM, Rucker N and Gomer
CJ: Celecoxib and NS-398 enhance photodynamic therapy by increasing
in vitro apoptosis and decreasing in vivo
inflammatory and angiogenic factors. Cancer Res. 65:9473–9478.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qiu R, Chen J, Sima J, Shen X, Liu D and
Shen J: NS398 induces apoptosis in non-small cell lung cancer
cells. J Cancer Res Clin Oncol. 138:119–124. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang LQ, Wang J, Jiang F, Xu L, Liu FY
and Yin R: Prognostic value of survivin in patients with non-small
cell lung carcinoma: a systematic review with meta-analysis. PLoS
One. 7:e341002012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kirkpatrick K, Ogunkolade W, Elkak A, et
al: The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular
endothelial growth factor (VEGF) in human breast cancer. Curr Med
Res Opin. 18:237–241. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao Q, Wang C, Zhu J, et al:
RNAi-mediated knockdown of cyclooxygenase2 inhibits the growth,
invasion and migration of SaOS2 human osteosarcoma cells: a case
control study. J Exp Clin Cancer Res. 30:262011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Falandry C, Canney PA, Freyer G and Dirix
LY: Role of combination therapy with aromatase and cyclooxygenase-2
inhibitors in patients with metastatic breast cancer. Ann Oncol.
20:615–620. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Choe MS, Zhang X, Shin HJ, Shin DM and
Chen ZG: Interaction between epidermal growth factor receptor- and
cyclooxygenase 2-mediated pathways and its implications for the
chemoprevention of head and neck cancer. Mol Cancer Ther.
4:1448–1455. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Buchanan FG, Holla V, Katkuri S, Matta P
and DuBois RN: Targeting cyclooxygenase-2 and the epidermal growth
factor receptor for the prevention and treatment of intestinal
cancer. Cancer Res. 67:9380–9388. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chong H, Vikis HG and Guan KL: Mechanisms
of regulating the Raf kinase family. Cell Signal. 15:463–469. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Anjum R and Blenis J: The RSK family of
kinases: emerging roles in cellular signalling. Nat Rev Mol Cell
Biol. 9:747–758. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cuevas BD, Abell AN and Johnson GL: Role
of mitogen-activated protein kinase kinase kinases in signal
integration. Oncogene. 26:3159–3171. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Peng CL, Guo W, Ji T, et al: Sorafenib
induces growth inhibition and apoptosis in human synovial sarcoma
cells via inhibiting the RAF/MEK/ERK signaling pathway. Cancer Biol
Ther. 8:1729–1736. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lu X, Tang X, Guo W, Ren T and Zhao H:
Sorafenib induces growth inhibition and apoptosis of human
chondrosarcoma cells by blocking the RAF/ERK/MEK pathway. J Surg
Oncol. 102:821–826. 2010. View Article : Google Scholar : PubMed/NCBI
|
